News & Views
Merck and Sanofi-aventis laboratories to collaborate on cancer research
Dec 20 2010
In particular, the companies' laboratories will work on testing different combinations of agents that could potentially be used to block specific pathways in cancer cells.
The research will involve Merck Serono's MEK inhibitor MSC1936369B, the PI3K/mTOR inhibitor SAR245409 from Sanofi-aventis and the Class I PI3K inhibitor SAR245408.
Dr Wolfgang Wein, Merck Serono's executive vice-president for oncology, said the need to create more personalised cancer care makes it a "logical step" to explore how "new, exciting molecules" can be combined across development pipelines.
Sanofi-aventis senior vice-president and head of global oncology Dr Debasish Roychowdhury added: "This collaboration reinforces our commitment to maximise our portfolio and to provide better treatments for patients with cancer."
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE